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Abstract
Objectives. To examine the predictive validity of the Gout Activity Score (GAS), its correlation with the Gout Impact
Scale (GIS) and their sensitivity to change.
Methods. Data from a clinical trial in which participants with one or more gout flares in the previous year were recruited
from primary care and randomized to nurse-led or continuing usual care were used in this study. GAS and GIS were
calculated as described, with higher scores indicating worse disease activity and quality of life, respectively. The cor-
relation between GAS and GIS was examined using Spearman’s correlation. Standardized response means (SRMs) were
calculated to assess sensitivity to change. The association between GAS at baseline and the number of flares in the next
12 months was evaluated using Poisson regression. Data analyses were performed using STATA version 14, with P-
values <0.05 being statistically significant.
Results. There was low positive correlation between GAS and gout concern overall and unmet treatment need sub-
scales of GIS (r= 0.340.45). Female sex associated independently with fewer gout flares, while increasing GAS, BMI and
age associated independently with frequent flares. Of all the outcome measures examined, GAS was the most respon-
sive to change (SRM 0.89 to 0.53). Of the GIS domains, the gout concern overall domain had the best sensitivity to
change (SRM 1.060.01).
Conclusion. GAS is sensitive to change, has predictive validity and correlates with relevant domains of GIS such as
gout concern overall. Additional independent validation of GAS is required before it can be adopted in clinical practice.
Key words: gout, disease activity, quality of life
Rheumatology key messages
. Gout activity score predicts future gout flares.
. Gout activity score is sensitive to change.
. Gout activity score correlates with some, but not all gout impact scale domains.
Introduction
Gout is the most common inflammatory arthritis world-
wide and is increasing in prevalence. It is estimated to
affect 23% of people in the USA and Europe [1, 2]. The
first disease-specific activity score for gout, the Gout
Activity Score (GAS), was developed in 2016 and
demonstrated low-level correlation with the HAQ and
Patient Acceptable Symptom State and moderate correl-
ation with pain [3, 4]. In a subsequent primary carebased
study, it demonstrated negligible to low correlation with
individual domains of the Gout Impact Scale (GIS), the
only disease-specific quality of life (QoL) measure for
gout [5]. The predictive validity of GAS and its sensitivity
to change have not been examined. It is important to
explore these properties of GAS to evaluate its validity
as an outcome measure. Similarly, the sensitivity to
change of GIS has not been examined in a clinical trial
involving urate-lowering treatment (ULT), having previ-
ously been investigated in a longitudinal observational
study, and in a trial of rilonacept or placebo for flare
prophylaxis [6, 7].
Therefore the objectives of this study were to examine
the correlation between GAS and GIS, examine the
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validity of GAS in predicting the number of gout flares and
evaluate the responsiveness of GAS and GIS, using data
from the Nottingham Gout Treatment Trial (phase II) [8, 9].
Methods
Data source
Data from the Nottingham Gout Treatment Trial (phase II)
were used. The details of this study have been published
elsewhere [8]. In brief, 517 community-derived adults with
gout having one or more gout flares in the 12 months prior
to recruitment were randomized 1:1 to either study arm
and followed for 2 years. Patients in the usual care arm
continued being treated by their general practitioner (GP),
while those in the nurse-led arm followed a protocol that
included patient education and engagement, addressing
illness perceptions and a treat-to-target ULT strategy, re-
flecting recommended best practice according to rheu-
matology gout management guidelines [10, 11].
Research assessments at baseline, 1 year and 2 years
included collection of demographic data, gout flares in
the previous 12 months, gout activity questionnaire (GAQ
2.0) [12], medications, comorbidities, anthropometric
measurements, tophus count and blood collection. The
study was approved by the East Midlands Nottingham
Research Ethics Committee (12/EM/0044) and registered
with the National Clinical Trials Registry (www.clinical-
trials.gov, ref: NCT01477346).
Calculation of outcome measures
GAS was calculated using the GAS3-step-c formula [3]. This
utilizes data on the self-reported number of attacks in the
previous 12 months, serum urate, patient-reported visual
analogue scale (VAS) of gout severity and the number of
tophi. The subscales of GIS, specifically the gout concern
overall, gout medication side effects, unmet gout treat-
ment need, well-being during attack and gout concern
during attack, were calculated as described by Hirsch et
al. [12]. Higher scores for GAS and GIS indicate worse
disease activity and QoL, respectively.
Gout status change
As flares are an important patient-centred outcome, par-
ticipants were classified into one of the four disease status
change groups based on the number of self-reported
flares in the 12 month period prior to study entry and the
number of gout flares in the 12 months prior to the final
2 year research assessment visit. The disease state
changes were
Flare free: No flares in the 12month period preceding
the 2year research visit.
Better: At least one fewer flare in the 12month period
preceding the 2year research visit compared with
the 12month period prior to study entry and not
meeting criteria for flare free.
Same: An equal number of flares in the two time
periods.
Worse: One or more flares in the 12month period
preceding the 2year assessment than in the
12month period prior to study entry.
Statistical analysis
Mean (S.D.) and n (%) were used for descriptive purposes.
As GIS and GAS were non-normally distributed,
Spearman’s correlation test was used. The associations
between baseline GAS and the number of flares in the
next 12 months were examined using Poisson regression
and were adjusted for age (tertiles); sex; BMI (tertiles); use
of either NSAIDs, corticosteroids or colchicine at the
baseline visit (yes/no) and the duration for which each
participant was in the trial up to week 52. Crude and ad-
justed incidence rate ratios (IRRs) and 95% CIs were cal-
culated to examine associations. As participants
randomized to nurse-led care received up-titrated ULT,
which may affect flare frequency, this analysis was re-
stricted to participants in the usual care group alone a
priori. A sensitivity analysis was performed, restricted to
participants on stable dose ULT or not on any ULT.
Responsiveness to change was estimated using the
standardized response mean (SRM). The SRM is calcu-
lated as a ratio of the mean change and S.D. of change
scores from baseline and the end-of-study visit [13]. Data
from all participants completing the 2 year randomized
controlled trial and completing the GIS at the baseline
and final study visit were included in the assessment of
responsiveness to change. All data analysis was per-
formed using STATA version 14 (StataCorp, College
Station, TX, USA).
Results
Data from 517 study participants, 262 receiving usual (GP-
led) care and 255 receiving nurse-led care of gout, were
included in this study. Briefly, there were 461 (89.2%)
men, 203 (39.3%) on ULT, and 58 (11.2%) had one or
more tophus at the baseline visit. Their mean age, BMI
and serum urate was 62.89 years (S.D. 11.40), 29.79 kg/
m2 (S.D. 5.07) and 7.41 mg/dl (S.D. 1.67), respectively. Their
median disease duration and VAS pain were 9.54 years
[interquartile range (IQR) 3.6218.20] years and 4 mm (IQR
17), respectively.
There was low positive correlation between gout con-
cern overall and the unmet treatment need subscales of
GIS and GAS at all time points (Supplementary Table S1,
available at Rheumatology online). Female sex associated
with fewer gout flares [adjusted IRR (aIRR) 0.71 (95% CI
0.51, 1.00)], while increasing GAS quartiles [aIRR 1.34
(95% CI 1.23, 1.46)], BMI tertiles [aIRR 1.16 (95% CI
1.03, 1.30)] and age tertiles [aIRR 1.12 (95% CI 1.00,
1.26)] associated with frequent flares (Table 1).
Participants taking anti-inflammatory drugs at the baseline
visit had more flares. Twenty-seven people in the usual
care arm commenced on ULT or changed its dose in the
12 months following the baseline visit. The association be-
tween increasing GAS quartiles and number of gout flares
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did not change when these participants were excluded in
a sensitivity analysis [aIRR 1.20 (95% CI 0.86, 1.68), 2.08
(1.52, 2.83), 2.56 (1.87, 3.50) in the second, third and
fourth GAS quartile with GAS in the first quartile as
referent].
Of all the outcome measures examined, GAS was the
most responsive to change, with SRMs ranging from 0.89
in the flare free to 0.53 in those with worsening gout
(Table 2). Of the GIS domains, the gout concern overall
domain had the best sensitivity to change.
Discussion
This is the first study to examine the predictive validity and
sensitivity to change of the GAS. It reports that increasing
GAS associates with gout flares over a 12 month period,
providing construct validity. GAS is the first composite
disease activity measure for gout. It can be implemented
easily in clinical practice and does not have any additional
cost implications. The measurement and categorization of
the DAS enables practitioners to communicate with pa-
tients clearly and increase treatment if necessary.
Widespread use of such DASs has resulted in improved
standards of care in other rheumatic conditions, such as
RA. It is anticipated that the development and validation of
a DAS for gout will improve the quality of care for gout.
In a previous study, gout patients meeting the prelimin-
ary definition of remission had a GAS 42.78 [5]. Scire et
al. [3] reported that a GAS <2.5 had the best ability to
discriminate gout cases in remission. Taken together,
these studies suggest that a GAS <2.5 is a reasonable
long-term treatment target for gout. However, further re-
search is required to identify the GAS cut-offs that repre-
sent moderate and high disease activity.
The GIS is the only disease-specific QoL instrument for
gout. Our study demonstrates that the GAS has low posi-
tive correlation with the gout concern overall and unmet
gout treatment need domains of the GIS, but poor to no
correlation with the other three GIS domains. This is an
expected finding, as the other three domains of the GIS
are centred on side effects of treatment or QoL during
flares. The magnitude of correlation between the GAS
and GIS were comparable over a 2 year period and be-
tween intervention and control groups, suggesting that the
relationship between the GAS and individual domains of
the GIS is stable over time and between disease states.
There is no agreed definition of worsening of the clinical
disease state in gout. We used an empirical definition of at
least one more or one fewer gout flare in a 12 month
period to indicate a clinical disease state change in gout
based on feedback from patients and public involvement
in research meetings in Nottingham, UK (AA personal
communication). Using this definition, both the GAS and
the gout concern overall and unmet treatment need do-
mains of the GIS were sensitive to change. Numerically,
the GAS had the greatest spread of SRMs and reflected
disease worsening with a negative score. Thus it meets
the truth and discrimination domains of the OMERACT
filter 2.0 [14]. However, none of the outcome measures
could differentiate between flare free and improved dis-
ease states of gout, and further refinement in outcome
measures may be necessary.
This study reports that the GIS is more sensitive to
change than previously reported. For example, the gout
concern overall and unmet gout treatment need domains
of the GIS had a sensitivity to change of 0.43 and 0.22,
respectively, in previous studies [6, 7]. In this study, the
mean change in the unmet gout treatment need domain of
the GIS among people whose disease status remained
unchanged was smaller than the minimally important dif-
ferences for them reported previously (5.76 vs 6.88),
whereas the mean change in the gout concern overall
domain was only marginally higher compared with previ-
ous reports (9.69 vs 7.16), providing external validity to our
findings [7]. We found an association between male sex,
increasing BMI and frequent gout flares as reported
TABLE 1 Association between disease and demographic factors and GAS at baseline and number of flares during the
next 12 months
Variable IRR (95% CI) P-value aIRR (95% CI) P-value
Gender Male 1 1
Female 0.69 (0.50, 0.95) 0.024 0.71 (0.51, 1.00) 0.047
Age (years) 460.00 1 1
60.0269.49 1.59 (1.26, 2.01) <0.001 1.71 (1.35, 2.16) <0.001
569.60 1.06 (0.83, 1.36) 0.644 1.33 (1.03, 1.73) 0.030
BMI (kg/m2) 427.46 1 1
27.4730.83 1.73 (1.39, 2.17) <0.001 1.54 (1.23, 1.94) <0.001
530.84 1.34 (1.06, 1.70) 0.015 1.29 (1.01, 1.64) 0.042
GAS 43.46 1 1
3.474.33 1.78 (1.32, 2.42) <0.001 1.61 (1.18, 2.18) <0.001
4.345.39 2.05 (1.53, 2.75) <0.001 2.02 (1.50, 2.72) <0.001
55.40 2.81 (2.11, 3.74) <0.001 2.61 (1.96, 3.49) <0.001
Anti-inflammatory drugs No 1 1
Yes 1.56 (1.26, 1.93) <0.001 1.45 (1.15, 1.81) 0.001
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previously [15, 16]. However, the observed association
between age and gout flares is consistent with some but
not all studies [1518].
The strengths of this study include large sample size,
community-based recruitment and standardized assess-
ment of tophi. However, there are several caveats to this
study. First, the number of gout flares in the 12 months
prior to the baseline visit was self-reported, whereas the
number of flares in the next 24 months was recorded pro-
spectively. Furthermore, we did not utilize the recent def-
inition of gout flares since the start of this study predated
its publication [19].
In conclusion, the GAS is sensitive to change and has
predictive validity. However, further research is required
to define the GAS cut-offs that can be used to define
states of high, moderate and low disease activity before
it can be used in the clinic.
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